Splenic marginal zone lymphoma overview: Difference between revisions
No edit summary |
No edit summary |
||
Line 5: | Line 5: | ||
'''Splenic marginal zone lymphoma''' (SMZL) is a [[lymphoma]] comprised of [[B-cells]] that replace the normal architecture of the [[white pulp]] of the [[spleen]]. Genes involved in the pathogenesis of splenic marginal zone lymphoma include [[immunoglobulin]] genes and CDK6 gene. On microscopic histopathological analysis, [[B-cells]], villous lymphocytes, and [[sinus]] invasion are characteristic findings of splenic marginal zone lymphoma. <ref name="who1">[http://www.iarc.fr/WHO-BlueBooks/BBwebsite/bb3.html] Jaffe E.S., Harris N.L., Stein H., Vardiman J.W. (eds): '''World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues.''' IARC Press: Lyon 2001 </ref>There are no established causes for splenic marginal zone lymphoma. Splenic marginal zone lymphoma must be differentiated from other diseases such as [[chronic lymphocytic leukemia]], [[follicular lymphoma]], and [[mantle cell lymphoma]].<ref name=cancer.gov> Splenic marginal zone lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd5327/. Accessed on January 14, 2016</ref> The incidence of splenic marginal zone lymphoma increases with age; the median age at diagnosis is 50 years. Splenic marginal zone lymphoma affects men and women equally.<ref name="ber1"> | '''Splenic marginal zone lymphoma''' (SMZL) is a [[lymphoma]] comprised of [[B-cells]] that replace the normal architecture of the [[white pulp]] of the [[spleen]]. Genes involved in the pathogenesis of splenic marginal zone lymphoma include [[immunoglobulin]] genes and CDK6 gene. On microscopic histopathological analysis, [[B-cells]], villous lymphocytes, and [[sinus]] invasion are characteristic findings of splenic marginal zone lymphoma. <ref name="who1">[http://www.iarc.fr/WHO-BlueBooks/BBwebsite/bb3.html] Jaffe E.S., Harris N.L., Stein H., Vardiman J.W. (eds): '''World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues.''' IARC Press: Lyon 2001 </ref>There are no established causes for splenic marginal zone lymphoma. Splenic marginal zone lymphoma must be differentiated from other diseases such as [[chronic lymphocytic leukemia]], [[follicular lymphoma]], and [[mantle cell lymphoma]].<ref name=cancer.gov> Splenic marginal zone lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd5327/. Accessed on January 14, 2016</ref> The incidence of splenic marginal zone lymphoma increases with age; the median age at diagnosis is 50 years. Splenic marginal zone lymphoma affects men and women equally.<ref name="ber1"> | ||
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10706860&query_hl=7&itool=pubmed_ExternalLink] | [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10706860&query_hl=7&itool=pubmed_ExternalLink] | ||
Berger F, Felman P, Thieblemont C, Pradier T, Baseggio L, Bryon PA, Salles G, Callet-Bauchu E, Coiffier B. "Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients." '''Blood'''. 2000 Mar 15;95(6):1950-6. PMID: 10706860</ref> | Berger F, Felman P, Thieblemont C, Pradier T, Baseggio L, Bryon PA, Salles G, Callet-Bauchu E, Coiffier B. "Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients." '''Blood'''. 2000 Mar 15;95(6):1950-6. PMID: 10706860</ref> There are no established risk factors for splenic marginal zone lymphoma. According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for splenic marginal zone lymphoma.<ref> Recommendations. U.S Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=SPLENIC+MARGINAL+ZONE+LYMPHOMA Accessed on December 23, 2015</ref> Low [[Hemoglobin]] levels, high [[lactate dehydrogenase]] levels, low blood serum [[albumin]] levels, and genetic mutations such as mutations in ''NOTCH2'' are associated with poor prognosis among patients with splenic marginal zone lymphoma. According to the Lugano classification, there are four stages of splenic marginal zone lymphoma based on the number of nodes and extranodal involvement. The most common symptoms of splenic marginal zone lymphoma include [[fever]], [[weight loss]], skin rash, [[night sweats]], chest pain, [[abdominal pain]], [[bone pain]], and painless swelling in the neck, axilla, groin, thorax, and abdomen. Common physical examination findings of splenic marginal zone lymphoma include [[fever]], [[rash]], [[ulcer]], [[splenomegaly]], chest tenderness, abdomen tenderness, bone tenderness, [[Lymphadenopathy|peripheral lymphadenopathy]], and [[Lymphadenopathy|central lymphadenopathy]].<ref name= seer>Splenic marginal zone lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd5327/ Accessed on December 22, 2015 </ref> | ||
==Pathophysiology== | ==Pathophysiology== | ||
Line 19: | Line 17: | ||
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10706860&query_hl=7&itool=pubmed_ExternalLink] | [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10706860&query_hl=7&itool=pubmed_ExternalLink] | ||
Berger F, Felman P, Thieblemont C, Pradier T, Baseggio L, Bryon PA, Salles G, Callet-Bauchu E, Coiffier B. "Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients." '''Blood'''. 2000 Mar 15;95(6):1950-6. PMID: 10706860</ref> | Berger F, Felman P, Thieblemont C, Pradier T, Baseggio L, Bryon PA, Salles G, Callet-Bauchu E, Coiffier B. "Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients." '''Blood'''. 2000 Mar 15;95(6):1950-6. PMID: 10706860</ref> | ||
==Risk Factors== | |||
There are no established risk factors for splenic marginal zone lymphoma. | |||
==Screening== | |||
According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for splenic marginal zone lymphoma.<ref> Recommendations. U.S Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=SPLENIC+MARGINAL+ZONE+LYMPHOMA Accessed on December 23, 2015</ref> | |||
==Prognosis== | |||
Low [[Hemoglobin]] levels, high [[lactate dehydrogenase]] levels, low blood serum [[albumin]] levels, and genetic mutations such as mutations in ''NOTCH2'' are associated with poor prognosis among patients with splenic marginal zone lymphoma. | |||
==Staging== | |||
According to the Lugano classification, there are four stages of splenic marginal zone lymphoma based on the number of nodes and extranodal involvement. | |||
==Symptoms== | |||
The most common symptoms of splenic marginal zone lymphoma include [[fever]], [[weight loss]], skin rash, [[night sweats]], chest pain, [[abdominal pain]], [[bone pain]], and painless swelling in the neck, axilla, groin, thorax, and abdomen. | |||
==Physical Examination== | |||
Common physical examination findings of splenic marginal zone lymphoma include [[fever]], [[rash]], [[ulcer]], [[splenomegaly]], chest tenderness, abdomen tenderness, bone tenderness, [[Lymphadenopathy|peripheral lymphadenopathy]], and [[Lymphadenopathy|central lymphadenopathy]].<ref name= seer>Splenic marginal zone lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd5327/ Accessed on December 22, 2015 </ref> | |||
==References== | ==References== |
Revision as of 13:49, 18 January 2016
Splenic marginal zone lymphoma Microchapters |
Differentiating Splenic marginal zone lymphoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Splenic marginal zone lymphoma overview On the Web |
American Roentgen Ray Society Images of Splenic marginal zone lymphoma overview |
Directions to Hospitals Treating Splenic marginal zone lymphoma |
Risk calculators and risk factors for Splenic marginal zone lymphoma overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [4]
Overview
Splenic marginal zone lymphoma (SMZL) is a lymphoma comprised of B-cells that replace the normal architecture of the white pulp of the spleen. Genes involved in the pathogenesis of splenic marginal zone lymphoma include immunoglobulin genes and CDK6 gene. On microscopic histopathological analysis, B-cells, villous lymphocytes, and sinus invasion are characteristic findings of splenic marginal zone lymphoma. [1]There are no established causes for splenic marginal zone lymphoma. Splenic marginal zone lymphoma must be differentiated from other diseases such as chronic lymphocytic leukemia, follicular lymphoma, and mantle cell lymphoma.[2] The incidence of splenic marginal zone lymphoma increases with age; the median age at diagnosis is 50 years. Splenic marginal zone lymphoma affects men and women equally.[3] There are no established risk factors for splenic marginal zone lymphoma. According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for splenic marginal zone lymphoma.[4] Low Hemoglobin levels, high lactate dehydrogenase levels, low blood serum albumin levels, and genetic mutations such as mutations in NOTCH2 are associated with poor prognosis among patients with splenic marginal zone lymphoma. According to the Lugano classification, there are four stages of splenic marginal zone lymphoma based on the number of nodes and extranodal involvement. The most common symptoms of splenic marginal zone lymphoma include fever, weight loss, skin rash, night sweats, chest pain, abdominal pain, bone pain, and painless swelling in the neck, axilla, groin, thorax, and abdomen. Common physical examination findings of splenic marginal zone lymphoma include fever, rash, ulcer, splenomegaly, chest tenderness, abdomen tenderness, bone tenderness, peripheral lymphadenopathy, and central lymphadenopathy.[5]
Pathophysiology
Genes involved in the pathogenesis of splenic marginal zone lymphoma include immunoglobulin genes and CDK6 gene. On microscopic histopathological analysis, B-cells, villous lymphocytes, and sinus invasion are characteristic findings of splenic marginal zone lymphoma. [1]
Causes
There are no established causes for splenic marginal zone lymphoma.
Differential Diagnosis
Splenic marginal zone lymphoma must be differentiated from other diseases such as chronic lymphocytic leukemia, follicular lymphoma, and mantle cell lymphoma.[2]
Epidemiology and demographics
The incidence of splenic marginal zone lymphoma increases with age; the median age at diagnosis is 50 years. Splenic marginal zone lymphoma affects men and women equally.[3]
Risk Factors
There are no established risk factors for splenic marginal zone lymphoma.
Screening
According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for splenic marginal zone lymphoma.[6]
Prognosis
Low Hemoglobin levels, high lactate dehydrogenase levels, low blood serum albumin levels, and genetic mutations such as mutations in NOTCH2 are associated with poor prognosis among patients with splenic marginal zone lymphoma.
Staging
According to the Lugano classification, there are four stages of splenic marginal zone lymphoma based on the number of nodes and extranodal involvement.
Symptoms
The most common symptoms of splenic marginal zone lymphoma include fever, weight loss, skin rash, night sweats, chest pain, abdominal pain, bone pain, and painless swelling in the neck, axilla, groin, thorax, and abdomen.
Physical Examination
Common physical examination findings of splenic marginal zone lymphoma include fever, rash, ulcer, splenomegaly, chest tenderness, abdomen tenderness, bone tenderness, peripheral lymphadenopathy, and central lymphadenopathy.[5]
References
- ↑ 1.0 1.1 [1] Jaffe E.S., Harris N.L., Stein H., Vardiman J.W. (eds): World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues. IARC Press: Lyon 2001
- ↑ 2.0 2.1 Splenic marginal zone lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd5327/. Accessed on January 14, 2016
- ↑ 3.0 3.1 [2] Berger F, Felman P, Thieblemont C, Pradier T, Baseggio L, Bryon PA, Salles G, Callet-Bauchu E, Coiffier B. "Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients." Blood. 2000 Mar 15;95(6):1950-6. PMID: 10706860
- ↑ Recommendations. U.S Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=SPLENIC+MARGINAL+ZONE+LYMPHOMA Accessed on December 23, 2015
- ↑ 5.0 5.1 Splenic marginal zone lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd5327/ Accessed on December 22, 2015
- ↑ Recommendations. U.S Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=SPLENIC+MARGINAL+ZONE+LYMPHOMA Accessed on December 23, 2015